Stock Scorer

Incyte Corporation (INCY) · Peers

Incyte against the 14 other companies here in its SEC industry, Services-Commercial Physical & Biological Research. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 15, highest first.

Measure by measure

MeasureINCYPeer medianRank
Market value $22.59B median $278.05M 2 of 14
P/E 15.8× median 58.6× 5 of 5
Forward P/E 36.2× median 26.5× 2 of 6
EV/EBITDA 11.0× median 23.0× 6 of 6
P/S 4.2× median 4.6× 8 of 13
FCF yield 6.4% median -2.5% 2 of 14
Gross margin 92.5% median 22.7% 1 of 7
Operating margin 30.0% median -65.3% 1 of 13
Net margin 26.7% median -25.8% 1 of 12
ROIC 73.6% median -5.5% 1 of 10
ROE 25.5% median -17.0% 3 of 12
Revenue growth (4y, yearly) 14.5% median -0.6% 3 of 12
EPS growth (yearly) 10.7% median 12.2% 3 of 4
Current ratio 3.7× median 1.4× 4 of 15
Stock pay / revenue 4.7% median 2.1% 7 of 14
Share count change -4.7% median 1.5% 10 of 14

Green where Incyte is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.

The peers, largest first

CompanyMarket valueP/EROICScore
INCYIncyte Corporation $22.59B P/E 15.8× 73.6% 8.8
IQVIQVIA Holdings Inc $44.55B P/E 32.2× 8.6% 6.0
MEDPMedpace Holdings, Inc. $17.31B P/E 35.2× – 7.4
CRLCharles River Laboratories $14.38B P/E – 0.4% 4.0
ICLRIcon PLC $13.03B P/E 307.7× 2.2% 5.4
OABIOmniAb, Inc. $679.70M P/E – -18.3% 4.1
NRCNational Research Corp $447.26M P/E 81.9× 12.0% 4.6
ONMDOneMedNet Corp $278.05M P/E – – 3.5
MXCTMaxcyte, Inc. $133.65M P/E – -62.2% 4.3
BIAFbioAffinity Technologies, Inc. $30.22M P/E – -505.1% 3.5
VSBCVitaspring Biomedical Co. Ltd. $26.33M P/E – – 2.9
CBIHCannabis Bioscience International Holdings, Inc. $2.33M P/E – – 2.8
ISPCiSpecimen Inc. $2.31M P/E – – 3.5
FOXOFoxo Technologies Inc. $182,393 P/E – -5.5% 4.4
ABSIAbsci Corp – P/E – -220.9% 3.3

The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.